Wall St. extends run of record highs; services data upbeat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Wells Fargo (WFC) PT Raised to $57 at UBS on 3Q17 U.S. Banking Preview; 'Economic Growth Conditions to Drive Bank Stocks'
October 6, 2017 10:11 AM EDTUBS raised its price target on Wells Fargo (NYSE: WFC) to $57.00 (from $56.00) while maintaining a Neutral rating, following a third quarter 2017 U.S. Banking preview.
Analyst Saul Martinez notes a positive outlook following the third quarter 2017 U.S. Banking preview, as the... More
Netflix (NFLX) PT Raised to $225 at Rosenblatt Following Announced Price Increase
October 6, 2017 9:27 AM EDTRosenblatt raised its price target on Netflix (NASDAQ: NFLX) to $225.00 (from $200.00) while maintaining a Buy rating following the company's announcement that it will be raising prices in the US. The company will raise prices by 10% on its most popular service, 17% on its... More
Netflix (NFLX) PT Raised to $180 at Jefferies Following Announced Priceing Move
October 6, 2017 7:04 AM EDTJefferies raised its price target on Netflix (NASDAQ: NFLX) to $180.00 (from $165.00) while maintaining a Hold rating. The company plans to raise the price of its standard / premium plans by $1 / $2 per mo., respectively. Press reports indicate that the new prices will take place immediately for new US... More
Teva Pharma (TEVA) PT Lowered to $15 at Morgan Stanley
October 5, 2017 8:58 AM EDTMorgan Stanley lowered its price target on Teva Pharma (NYSE: TEVA) to $15.00 (from $16.00) while maintaining a Underweight rating.
... MoreTeva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'
October 4, 2017 12:17 PM EDTBarclays lowered its price target on Teva Pharma (NYSE: TEVA) to $21.00 (from $23.00) while maintaining a Equalweight rating, following an update on the U.S. Specialty Pharmaceutical industry, as the FDA recently approved a generic Copaxone formulation.
Analyst Douglas Tsao notes a... More
Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform
October 4, 2017 10:44 AM EDTCowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while maintaining a Market Perform rating. Cowen updated its model to reflect a potential $800MM in generic Copaxone contribution in 2018, and then modestly declining with other competition.
With this approval the... More
